The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Three decision domains shaping sterile drug product success
Explore how development, manufacturing, and stability decisions shape outcomes across the sterile drug product lifecycle—and uncover the hidden costs of delayed decision-making.
Sterile development is often described as a sequence of activities: formulation development, process development, fill-finish manufacturing, analytical testing, technology transfer, and commercial scale-up.
In practice, however, success is shaped less by these individual activities than by the decisions that connect them. Decisions made at one stage can create constraints that only become apparent later in development.
Development, manufacturing, and stability decisions are interconnected
In this article, we explore how three critical decision domains have an outsized impact on whether sterile programs maintain momentum as they progress towards commercialization:
- Development decisions that influence future manufacturing readiness
- Manufacturing decisions that determine execution success
- Stability decisions that shape long-term lifecycle flexibility
The article also examines the hidden costs of delayed decision-making, including the downstream consequences that frequently emerge as a result.
Download the article to learn how making the right decisions at the right time can help biopharma companies keep their sterile programs on track.
